XTL Biopharma CFO Resigns, New CFO Appointed
Ticker: XTLB · Form: 6-K · Filed: Dec 5, 2025 · CIK: 1023549
| Field | Detail |
|---|---|
| Company | Xtl Biopharmaceuticals Ltd (XTLB) |
| Form Type | 6-K |
| Filed Date | Dec 5, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $300M, $700M |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, cfo-appointment, resignation
TL;DR
CFO Itay Weinstein out Dec 11, Niv Segal in. No drama.
AI Summary
XTL Biopharmaceuticals Ltd. announced on December 5, 2025, that its Chief Financial Officer, Itay Weinstein, will resign effective December 11, 2025. His resignation is not due to any disagreements. To fill the vacancy, the Board of Directors approved the appointment of Niv Segal as the new CFO on November 30, 2025.
Why It Matters
This filing signals a leadership change in the finance department of XTL Biopharmaceuticals, which could impact investor confidence and financial strategy.
Risk Assessment
Risk Level: medium — Changes in key financial leadership can introduce uncertainty regarding the company's financial direction and stability.
Key Players & Entities
- XTL Biopharmaceuticals Ltd. (company) — The company making the announcement.
- Itay Weinstein (person) — Resigning Chief Financial Officer.
- Niv Segal (person) — Appointed Chief Financial Officer.
- December 5, 2025 (date) — Date of the announcement.
- December 11, 2025 (date) — Effective date of CFO resignation.
- November 30, 2025 (date) — Date the Board approved the new CFO appointment.
FAQ
When is Itay Weinstein's resignation as CFO effective?
Itay Weinstein's resignation as CFO is effective December 11, 2025.
Why is Itay Weinstein resigning?
The filing states that Mr. Weinstein's resignation was not a result of any disagreement with the Company or its management.
Who has been appointed as the new CFO?
Mr. Niv Segal has been appointed as the new CFO.
When was Niv Segal appointed as CFO?
The Board of Directors approved the appointment of Mr. Niv Segal on November 30, 2025.
What is the company's primary business?
XTL Biopharmaceuticals Ltd. is in the Pharmaceutical Preparations industry (SIC code 2834).
Filing Stats: 419 words · 2 min read · ~1 pages · Grade level 8.9 · Accepted 2025-12-05 16:30:22
Key Financial Figures
- $300M — Labs, where he led the company’s $300M acquisition by Playtika, and as the Chi
- $700M — cial Officer of Beach Bum, managing its $700M acquisition process. Earlier, Mr. Segal
Filing Documents
- ea0268692-6k_xtlbio.htm (6-K) — 12KB
- 0001213900-25-118747.txt ( ) — 13KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. XTL BIOPHARMACEUTICALS LTD. Date: December 5, 2025 By: /s/ Noam Band Noam Band Chief Executive Officer 2